KR20090098425A - Composition comprising placenta extract as an effective component for improving gastrointestinal disease - Google Patents

Abstract

A composition for treating gastric disorder, which contains placental extract as an active ingredient is provided to suppress the colony formation of Helicobacter pylori. A composition for treating gastric disorder comprises a placental extract as an active ingredient. A method for manufacturing the placental extract comprises: a step of pulverizing placenta in the sized of 2~5 mm; a step of adding lipase and water to react the placenta at 39~45°C for five to ten hours; a step of adding emulsifier and collecting suspension; a step of adding water and protease and collecting at 28~40°C for 12~20 hours; and a step of mixing suspension.

Description

Composition comprising Placenta extract as an effective component for improving gastrointestinal disease}

The present invention relates to a composition for improving gastrointestinal diseases containing placenta extract as an active ingredient.

Gastritis and gastric ulcer refers to a condition in which the defects caused by damage to the upper digestive tract due to the action of gastric acid and pepsin invade below the gastric mucosal layer. Gastritis and gastric ulcers are one of the most common diseases in the world, and more than half of the US adult population and 90% of adults in many developing countries, including Korea, are infected with H. pylori (Scrip, 1993, 1820, 18).

This disease is characterized by acute and ulceration, which can be treated with mental and physical stability, diet, medication, etc., but it is not likely to be cured because of the high probability of recurrence within a certain period of time. , Complications such as pyloric stenosis and perforation (Jeen, YT and Hyun, JH 1991). Gastritis and gastric ulcers are not caused by one cause, but a combination of factors. Shay and Sun (Shay et al., 1945) in 1963 argued that gastric mucosal damage is caused by a breakdown of attack and defense factors, and this "Balance theory" has been accepted to date. The identification of Helicobacter pylori (H. pylori) by Marshall has led to new findings on the pathophysiology of gastritis, gastric ulcer and duodenal ulcer.

In the past, anti-ulcer drugs have been mainly focused on pharmacological action that inhibits attack factors, but when gastric ulcers are treated only by controlling the production and secretion of hydrochloric acid, the recurrence rate is high. Required. Helicobacter as a Pathogen of Recent Peptic Ulcer Disease Gram-negative bacillus called pylori is pointed out, and pathogenic microorganisms generate free radicals through neutrophils, and the highly active hydroxyl radicals attack the mucosal cells of digestive tract tissues to produce lipid peroxide of the tissue, causing tissue damage. It turns out that it is new.

Placenta, on the other hand, nucleic acid components such as essential amino acids, melatonin, RNA, DNA, antioxidants, SOD (Super Oxide Dismutase), hyaluronic acid (Hyaluronic acid), antioxidants, immune cofactors (cytokine), placental peptide, insulin-like growth It contains growth factors and cytokines such as insulin-like-growth factor, epidermal growth factors (EGF), and unique senescent cell activating factors (SCAF). It is known to be useful for recovery, immunity, etc., and is attracting attention as a raw material for health functional food.

The present inventors, along with the analysis of the active ingredient of the placenta extract, in order to find out whether it can be applied to the digestive system, especially gastrointestinal diseases, intestinal gastrointestinal diseases by verifying the efficacy of gastric function improvement through in vivo and in vitro tests The use for improvement was confirmed and the present invention was completed.

An object of the present invention is to provide a new use of the placenta extract by presenting a composition for improving gastrointestinal diseases containing the placenta extract as an active ingredient.

In addition, an object of the present invention is to provide a health food and pharmaceutical composition for improving gastrointestinal diseases comprising the composition.

In order to achieve the above object,

According to one aspect of the invention,

It can provide a composition for improving gastrointestinal diseases containing placenta extract as an active ingredient.

In addition, according to another aspect of the present invention, it is possible to provide a pharmaceutical composition for improving gastrointestinal disease comprising the composition.

In addition, according to another aspect of the present invention, it is possible to present a health food for improving gastrointestinal disease comprising the composition.

Hereinafter, the present invention will be described in detail.

The placenta raw material of the placenta extract of the present invention is not particularly limited as long as it is a placenta of mammals such as humans, sheep, cows, dogs, and pigs, but preferably, pig placenta can be used. Porcine placenta not only has the advantages of easy recovery and large amounts, but also has been found to be surprisingly similar to the molecular structure of placenta among mammalian placenta.

In order to prepare the placenta extract of the present invention, the placenta must first be collected, and in particular, the normal placenta of swine, which has been verified by a veterinarian, is collected in a freezer (-20 ° C. or lower) and collected. The frozen placenta is crushed into sawdust size (2 to 5 mm), put in a washing machine, washed with brine and dehydrated. It is not preferable to use frozen placenta as it is, and to use it after thawing and then use it in a subsequent process to cause contamination problems in subsequent processes.

Then, 1 to 5% by weight of lipase and the remaining amount of purified water are added to 20 to 30% by weight of the dehydrated pig placenta, followed by lipolysis reaction at 39 to 45 ° C. for 5 to 10 hours, preferably 7 to 8 hours.

The range of placental content and lipase content was chosen as the preferred range in terms of lipolysis efficiency. The reaction time and temperature were selected in the preferred range in consideration of lipolysis efficiency and unit cost.

After the lipolysis reaction, 1 to 5% by weight, preferably 2% by weight of vegetable emulsifier is added and stirred for 1.5 to 3 hours, and then the supernatant (hereinafter referred to as 'supernatant 1') and the placental residue are separated.

Subsequently, 0.5 to 5% by weight of protease and the remaining amount of water are added to 30 to 40% by weight of the placental residue and reacted at 28 to 40 ° C for 12 to 20 hours, preferably 15 to 17 hours. The protease is derived from a microorganism, a plant or an animal, and is not particularly limited, but papain is preferred.

The range of placental residue content and protease content was selected as a preferred range in consideration of hydrolysis efficiency. The hydrolysis reaction is carried out for 12 to 20 hours, preferably 15 to 17 hours. When the reaction is carried out for less than 12 hours, the hydrolysis reaction does not occur sufficiently. When the reaction is carried out for more than 20 hours, it is more than the time required for the desired hydrolysis efficiency, resulting in high production cost, which is uneconomical.

28-40 degreeC is preferable and, as for the said reaction temperature, 30-35 degreeC is more preferable. In the case of reacting below 28 ° C, the hydrolysis reaction may not occur properly, and in excess of 40 ° C, the enzyme may be inactivated.

The hydrolysis reaction product is centrifuged to recover the supernatant (hereinafter referred to as 'supernatant 2'), and the supernatant 1 and the supernatant 2 are mixed to prepare the pig placenta extract of the present invention.

The placental extract of the present invention may further include a process of terminating the hydrolysis reaction by heating to 85 to 100 ° C. after mixing the supernatants 1 and 2. This process can be carried out, for example, at 95 ° C. for 30 minutes.

In addition, the odor may be removed by adding and stirring activated carbon, may be subjected to a filtration process using a filter, and the reaction product may be stabilized by adding trehalose, an edible stabilizer. These processes can be performed by selecting or combining.

In the filtration process, it is preferable to perform filtration one or more times using a 0.1 to 10 μm filter. If the pore size of the filter is less than 0.1 μm, the filter is very precise and extremely expensive (ultrafiltration), and thus, the economy is inferior. If the pore size is more than 10 μm, there is a problem in that a float is formed in the final product and the product quality is significantly decreased.

Placenta extract of the present invention obtained through the filtration was carried out for amino acid analysis by weighing the total amount of nitrogen. Table 1 shows the results.

To produce the finished product, the container is sterilized at 200 ° C. for 2 hours to fill the extract of the present invention in a bottle, and the sterilized container is filled with the extract of the present invention, followed by high-pressure steam sterilization at 121 ° C. for 15 minutes. Can be.

Placenta extract of the present invention is, for example,

i) crushing the frozen pig placenta to 2-5 mm in size;

ii) adding water and lipase to the crushed pig placenta and reacting at 39 to 45 ° C. for 5 to 10 hours;

iii) recovering the supernatant by adding an emulsifier to the reaction solution of step ii) and then stirring;

iv) recovering the supernatant by adding protease and water to the residue of step iii) for 12 to 20 hours at 28 to 40 ° C; And

v) can be prepared by a manufacturing method comprising the step of mixing the supernatant of steps iii) and iv).

The present inventors tried to verify the gastrointestinal disease improvement effect of the prepared placenta extract.

Gastritis and gastric ulcer refers to a condition in which the defects caused by damage to the upper digestive tract due to the action of gastric acid and pepsin invade below the gastric mucosal layer. In the past, anti-ulcer drugs have been mainly focused on pharmacological action that inhibits attack factors, but when gastric ulcers are treated only by controlling the production and secretion of hydrochloric acid, the recurrence rate is high. Required. Recently, a Gram-negative bacillus called Helicobacter pylori has been pointed out as a pathogenic factor of peptic ulcer disease.

The inventors performed an antacid test, colony formation inhibitory test against Helicobacter pylori bacteria in vitro to determine whether the pig placenta extract of the present invention can be applied to gastrointestinal diseases such as gastritis and gastric ulcer.

In the antacid test, the pH change of the samples was determined by the NaOH consumption measured after preparing and treating gastric juice in the same state as gastritis, wherein the placental placenta extract of the present invention was found to have 50% inhibitory power. (Table 3). As a result of the test of the samples (Examples 2 to 4) according to the change in the treatment method, it was confirmed that there were antacids of 19.8, 12.5, and 21.2%, respectively. This means that the placental extract of the present invention has the ability to neutralize stomach acid.

Antimicrobial experiments were conducted at 10, 50, and 100 μg / mL concentrations on all samples, indicating that the number of colonies was reduced up to 50 μg / mL and that colony production was completely inhibited at 100 ug / mL. Table 4).

Therefore, the placental extract of the present invention can be effectively used to improve gastrointestinal diseases such as gastritis and gastric ulcer by effectively inhibiting gastric acid and effectively inhibiting colony formation of Helicobacter pylori, which is a factor of gastric ulcer.

In addition, according to another aspect of the present invention, it is possible to provide a pharmaceutical composition for improving gastrointestinal diseases, including a composition containing the placenta extract as an active ingredient.

The composition of the present invention may contain one or more active ingredients exhibiting the same or similar function in addition to the placenta extract. The composition of the present invention may contain one or more active ingredients exhibiting other functions in addition to the placenta extract.

The composition of the present invention may be prepared by including one or more pharmaceutically acceptable carriers in addition to the above-described active ingredients for administration. Pharmaceutically acceptable carriers may be used in combination with saline, sterile water, Ringer's solution, buffered saline, dextrose solution, maltodextrin solution, glycerol, ethanol and one or more of these components, if necessary, as antioxidants, buffers And other conventional additives such as bacteriostatic agents can be added. Diluents, dispersants, surfactants, binders and lubricants may also be added in addition to formulate into injectable formulations, pills, capsules, granules or tablets such as aqueous solutions, suspensions, emulsions and the like. Furthermore, it may be preferably formulated according to each disease or component by an appropriate method in the art or using a method disclosed in Remington's Pharmaceutical Science (Recent Edition), Mack Publishing Company, Easton PA.

The compositions of the present invention may be administered orally or parenterally (eg, intravenously, subcutaneously, intraperitoneally or topically) or orally, depending on the desired method, and the dosage may be weight, age, sex, health of the patient. The range varies depending on the condition, diet, administration time, administration method, excretion rate and severity of the disease. The daily dosage is 0.1 to 10 mg / kg, preferably 0.1 to 3 mg / kg, and more preferably administered once to several times a day.

When the placenta extract of the present invention was administered orally to mice, 50% lethal dose (LD ₅₀ ) by oral toxicity test was found to be at least 1 g / kg or more, which proved to be a safe substance.

The composition of the present invention may be used alone or in combination with methods using surgery, radiation therapy, hormone therapy, chemotherapy and biological response modifiers for the prevention and treatment of gastrointestinal diseases.

In addition, according to another aspect of the present invention, it is possible to present a health food for improving gastrointestinal disease comprising the composition.

The composition of the present invention can be added to health food for the purpose of improving gastrointestinal diseases. When the placenta extract of the present invention is used as a food additive, the placenta extract may be added as it is or may be used together with other food or food ingredients, and may be appropriately used according to a conventional method. The mixed amount of the active ingredient may be suitably determined depending on the purpose of use (prevention, health or therapeutic treatment). Generally, in the preparation of foods or beverages, the extract of the present invention is added in an amount of up to 100% by weight, preferably up to 50% by weight relative to the raw material. However, in the case of long-term intake for health and hygiene or health control, the amount may be below the above range, and the active ingredient may be used in an amount above the above range because there is no problem in terms of safety. .

There is no particular limitation on the kind of food. Examples of the food to which the substance can be added include dairy products including meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gums, ice cream, various soups, drinks, tea, drinks, Alcoholic beverages and vitamin complexes, and the like and include all of the health foods in the conventional sense.

The health beverage composition of the present invention may contain various flavors or natural carbohydrates, etc. as additional components, as in the general beverage. The above-mentioned natural carbohydrates are glucose, monosaccharides such as fructose, disaccharides such as maltose and sucrose, and polysaccharides such as dextrin and cyclodextrin, sugar alcohols such as xylitol, sorbitol and erythritol. As the sweetening agent, natural sweetening agents such as tautin and stevia extract, synthetic sweetening agents such as saccharin and aspartame, and the like can be used. The ratio of the natural carbohydrate is generally about 0.1 to 20 g, preferably about 1 to 10 g per 100 ml of the composition of the present invention.

In addition to the above components, the composition of the present invention may contain various nutrients, vitamins, electrolytes, flavors, colorants, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloidal thickeners, pH regulators, stabilizers, preservatives, glycerin, alcohols, And a carbonation agent used for the carbonated beverage. In addition, the composition of the present invention may contain a flesh for preparing natural fruit juice, fruit juice beverage and vegetable beverage. These components can be used independently or in combination. The proportion of such additives is not critical but is usually selected in the range of 0.05 to 50 parts by weight per 100 parts by weight of the composition of the present invention.

As described above, the placental extract of the present invention can be effectively used in the manufacture of pharmaceutical compositions or health foods for improving gastrointestinal diseases by effectively inhibiting the formation of gastric acid and Helicobacter pylori bacteria.

Hereinafter, the configuration and operation of the present invention through the preferred embodiment of the present invention will be described in more detail. However, this is presented as a preferred example of the present invention and in no sense can be construed as limiting the present invention. Details that are not described here will be omitted because those skilled in the art can sufficiently infer technically.

Example  One:

Frozen pig placenta was crushed into sawdust size (2 ~ 5 mm) with a crusher (Ilsung biaxial crusher ISM-410, Ilsung recycling) and put into a washing machine and washed with brine. 2 wt% of lipase (Lot # 18525, 2,000 U / mg, Sigma-Aldrich) and 73 wt% of water were added to 25 wt% of the dehydrated placenta and reacted at 43 ° C. for 8 hours.

Subsequently, 2% by weight of a vegetable emulsifier (green tea concentrate, an eco-friendly green tea emulsifier, and a halo-green farming method) was added, followed by stirring at 65 ° C. for 2 hours. After centrifugation, the supernatant 1 and the placental residue were separated, and to 35% by weight of the placenta residue, 3% by weight of papain (Lot # 1095981, 30 U / mg, Sigma-Aldich) and 62% by weight of water were added. After reacting at 35 ° C. for 16 hours, the supernatant 2 was separated by centrifugation. The supernatant 1 and the supernatant 2 were mixed and heated at 95 ° C. for 30 minutes, and 0.4% activated carbon was added at 65 ° C. to remove the odor while stirring, followed by filtration using a 1 μm filter and a 0.45 μm filter.

The composition from which the solid material was removed through the filtration was weighed in total nitrogen (final nitrogen was 2.06 mg / ml), and an amino acid analysis was performed (see Table 1). The total amount of nitrogen refers to the input of placenta prescribed by Korea Food and Drug Administration (KFDA). If this value is the same, the input of the first placenta can be regarded as the same.

Example  2:

5 g of the lyophilized powder of Example 1 was dissolved in 30 ml of distilled water, followed by ultrasonic extraction for 30 minutes, and then filtered through a 0.22 μm filter to freeze-dry the supernatant.

Example  3:

5 g of the lyophilized powder of Example 1 was dissolved in 30 ml of distilled water, and then ultrasonically extracted for 1 hour and then filtered through a 0.22 μm filter to freeze-dry the supernatant.

Example  4:

5 g of the lyophilized powder of Example 1 was dissolved in 30 ml of distilled water, and then ultrasonically extracted for 1.5 hours and then filtered through a 0.22 μm filter to freeze-dry the supernatant.

Test Example  1: Component Analysis and Quantitative Test

1-1: Amino Acid Analysis

Amino acid quantification of Example 1 of the present invention was carried out using Waters' AccQ-Tag Chemistry Package. This method is a precolumn derivatization method to analyze peptides and proteolytic amino acids.

The results are shown in Table 1, whereby, it can be seen that the placenta extract by the method of the present invention contains various amino acids in high concentrations.

TABLE 1

amino acid Lipase + Protease Extraction (Example 1) L-Aspartic acid 2.16 L-Serine 0.84 L-Glutamic acid 2.54 Aminoacetic acid 3.86 L-Arginine 1.54 L-Threonine 0.78 L-Alanine 2.04 L-Proline 2.51 L-Valine 1.03 L-Lysine 0.94 L-Leucine 1.21

Hereinafter, samples 1-2 to 1-5 were dissolved in 30ml of distilled water 5g lyophilized powder of the extract of Example 1 and then ultrasonically extracted for 30 minutes and then lyophilized using a 0.22 ㎛ filter.

1-2: Uronic acid  Quantitative Carbazole assay )

Uronic acid is a sugar derivative having an aldehyde or carboxyl group of sugars and plays an important role in detoxification of the human body, and is also important as a component of viscous polysaccharides such as hyaluronic acid and cord leucine sulfate.

Absorbance was measured using UV spectrophotometer at 530 nm by carbazole reaction using D-glucuronic acid lactone as standard. The sample was dissolved in distilled water, and the absorbance was measured using a UV spectrophotometer at 530 nm by Cabazole reaction, and the content was determined by calculating the content of D-glucuronic acid lactone.

1-3: Glycosaminoglycans  Quantitative Carbazole assay )

GAG is a component of protein sugar that accounts for most of the complex protein in connective tissue, and is currently increasing interest as an indicator of arthritis therapeutics.

Absorbance was measured by UV spectrophotometer at 530 nm by carbazole reaction using NZP chondroitin sulfate as standard. The sample was dissolved in distilled water and the absorbance was measured by UV spectrophotometer at 530 nm by carbazole reaction, and the content was determined by calculating the content of NZP chondroitin sulfate.

1-4: Sialic Acid Determination ( Warren assay )

Sialic acid is an amino sugar that is well known as a glycoprotein or glycolipid constituent sugar, and is particularly contained in mucin of the submandibular gland, and has an important physiological significance as an infection defense factor that helps immune function by inhibiting hemagglutination by influenza.

Using N-acetylneuraminic acid as a standard, the absorbance was measured by using a UV spectrophotometer at 549 nm by the Warren method. After the sample was hydrolyzed with 0.1 N sulfuric acid at 80 ° C. for 1 hour, the absorbance was measured using a UV spectrophotometer at 549 nm by the Warren method, and the content was determined by calculating the content of N-acetylneuraminic acid.

1-5: by enzyme Chondroitin  Sulfuric acid ( Chondroitin sulfate ) And hyaluronic acid ( Hyaluronic acid Disassembly

Chondroitin sulfate is a sulfated mucopolysaccharide that makes up connective tissues such as cartilage, blood vessel walls, and tendons. In vivo, it binds to proteins and together with collagen forms a major component of intercellular matter. Hyaluronic acid is a basic substance that makes up the living body and is the central substance for making skin. In particular, it acts to weave the skin cells and keeps the moisture of the skin as it attracts water molecules that are 214 times larger than its own.

Proteus Chondroitinase ABC (C2905, Sigma) derived from vulgaris was dissolved in 50 mM Tris-HCl 60 mM Sodium acetate buffer (pH 8.0) to 1U / ml. Using NZP CS as a standard, the standard and sample were dissolved at 10 mg / ml, mixed with buffer, 30 mU of enzyme, and reacted at 37 ° C. for 12 hours to analyze the content of chondroitin sulfate.

Strepromyces hyalurolyticus the Hyaluronidase (H1136, Sigma) Hyaluronidase 62 U Dissolve the standard and sample by using Hyaluronic acid as a standard, using a 62 U to 10 mg / ml to be 50 mM Sodium phosphate buffer (pH 7.1 ) containing 0.15 M NaCl derived from The reaction was carried out at 60 ℃ for 12 hours to analyze the content of hyaluronic acid.

The reaction was detected at UV 232 nm while maintaining a flow rate of 1 ml / min by connecting the SAX-HPLC column to AKTA Purifier (Amersham Phaimacia) with gradient NaCl 0M ~ 2M (pH 3.5).

Table 2 Unit% (w / w)

  sample Sialic acid GAG Uronic acid Chondroitin sulfate Hyaluronic acid Example 1 0.001 ± 0.000 2.109 ± 0.896 0.053 ± 0.04 1.16 2.82

As a result of analyzing the components of the sample, the results shown in Table 2 were obtained. Each reported a standard of 100% and quantified the percentage contained in the sample. The measurement was performed three times except for chondroitin sulfate and hyaluronic acid, and the average value was calculated and STDEV was calculated.

As shown in Table 2, the pig placenta extract prepared by the method of the present invention has a high content of various bioactive substances useful in the human body such as sialic acid, glycosaminoclican, uronic acid, chondroitin sulfate or hyaluronic acid. have.

Test Example  2 : On the rat  Acute toxicity test for oral administration

In order to determine whether the extract of the present invention has acute toxicity, the following experiment was performed.

Acute toxicity test was performed using 6 week-old SPF rats. Eight animals were orally administered with the composition of Example 2 of the present invention at a dose of 1 g / kg / 10 ml. After administration of the test substance, mortality, clinical symptoms, and changes in body weight were observed, and hematological and hematological examinations were performed. As a result, no significant clinical symptoms were observed in all animals treated with the test substance, no animals died, and no toxic changes were observed in weight change, blood test, blood biochemistry, and side findings. As a result, the composition of the present invention did not show a change in toxicity in rats up to 1 g / kg, and the minimum lethal dose (LD ₅₀ ) was determined to be a safe substance of at least 1 g / kg or more.

Test Example  3: Antacid (Acid neutralization ability) test

The antacid test method is a test method for determining the antacid power of an agent that reacts with gastric acid and changes the antacid test method specified in the Korean Pharmacopoeia to 0.1 N hydrochloric acid (Examples 2 to 4 of the present invention). After taking mg, the mixture was reacted for 1 hour in a shaking incubator at 37 ° C, and titrated with 0.1 N aqueous sodium hydroxide solution. Methyl orange was used as an indicator and hydrotalcite was used as a positive control (KEPCO Amendment, 2003). The results are shown in Table 3. The negative control group is titrated with 0.1 N NaOH in gastric juice conditions, that is, 0.1 N hydrochloric acid. As a result of the test of the samples (Examples 2 to 4) according to the change in the treatment method, it was confirmed that there were antacids of 19.8, 12.5, and 21.2%, respectively. This means that the placental extract of the present invention has the ability to neutralize stomach acid.

TABLE 3

sample NaOH consumption (volume) control(%) Negative control 122.67 ± 2.52 - Example 2 98.33 ± 6.11 19.8 Example 3 107.33 ± 6.43 12.5 Example 4 96.67 ± 2.31 21.2 hydrotalcite 104.67 ± 2.53 14.7

Test Example  4: Helicobacter To pylori  About Colony  formation Inhibitory ability  exam

The concentrations of H. pyroli at concentrations of 10, 50 and 100 μg / mL for all specimens As a result of testing the inhibition of colony formation (Table 3), the number of colonies was reduced up to 50 µg / mL, and colony production was completely suppressed at the concentration of 100 µg / mL (see FIG. 1A). Negative controls are on H. pyroli It is a medium which is not treated with a sample sample. 1A to 1E show the degree of colony formation and correspond to-, +, ++, +++, and ++++ in Table 4 in order.

Placenta extract of the present invention by strongly inhibited the growth of H. pyroli mitigate degradation resistance, mucosal hyperproliferation induced increase of carcinogenic N-nitroso compound such as gastric ulcer and for the mechanism of gastric H. pyroli carcinogen and secondary infection It is thought that the symptoms can be effectively prevented.

TABLE 4

sample dose (ug / ml) Degree of colony formation Negative control - ++++  Example 2 10 ++++ 50 ++ 100 -  Example 3 10 ++++ 50 ++ 100 -  Example 4 10 ++++ 50 ++ 100 -

While the embodiments of the present invention have been described with reference to the accompanying tables, the present invention is not limited to the above embodiments but can be embodied in various forms, and those skilled in the art to which the present invention belongs It will be appreciated that the invention may be embodied in other specific forms without changing the technical spirit or essential features of the invention. Therefore, it should be understood that the embodiments described above are exemplary in all respects and not restrictive.

1A to 1E are photographs showing the results of suppressing the degree of colony formation of Helicobacter pylori according to the concentration of the placental extract of the present invention, in order of-, +, ++, +++, ++ This is the picture for ++.

Claims (5)

Composition for improving gastrointestinal disease, containing placenta extract as an active ingredient. According to claim 1, The placenta extract is extracted from the placenta of pigs, composition for improving gastrointestinal disease. Placenta extract of claim 1 i) crushing the frozen pig placenta to 2-5 mm in size; ii) adding water and lipase to the crushed pig placenta and reacting at 39 to 45 ° C. for 5 to 10 hours; iii) recovering the supernatant by adding an emulsifier to the reaction solution of step ii) and then stirring; iv) recovering the supernatant by adding protease and water to the residue of step iii) for 12 to 20 hours at 28 to 40 ° C; And v) mixing the supernatant of steps iii) and iv); Prepared by the manufacturing method comprising a, gastrointestinal disease improvement composition. A pharmaceutical composition for improving gastrointestinal disease, comprising the composition of claim 1. Health foods for improving gastrointestinal disease comprising the composition of claim 1.

Images